JP6648040B2 - がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 - Google Patents

がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 Download PDF

Info

Publication number
JP6648040B2
JP6648040B2 JP2016569606A JP2016569606A JP6648040B2 JP 6648040 B2 JP6648040 B2 JP 6648040B2 JP 2016569606 A JP2016569606 A JP 2016569606A JP 2016569606 A JP2016569606 A JP 2016569606A JP 6648040 B2 JP6648040 B2 JP 6648040B2
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
eribulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016569606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516784A5 (enExample
JP2017516784A (ja
Inventor
デービッド コックス，
デービッド コックス，
アルトン クレマー，
アルトン クレマー，
シャロン マクゴニガル，
シャロン マクゴニガル，
ジャイ ウー，
ジャイ ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2017516784A publication Critical patent/JP2017516784A/ja
Publication of JP2017516784A5 publication Critical patent/JP2017516784A5/ja
Application granted granted Critical
Publication of JP6648040B2 publication Critical patent/JP6648040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016569606A 2014-05-28 2015-05-28 がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 Active JP6648040B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462003798P 2014-05-28 2014-05-28
US62/003,798 2014-05-28
US201462088200P 2014-12-05 2014-12-05
US62/088,200 2014-12-05
PCT/US2015/032990 WO2015184145A1 (en) 2014-05-28 2015-05-28 Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2017516784A JP2017516784A (ja) 2017-06-22
JP2017516784A5 JP2017516784A5 (enExample) 2018-07-05
JP6648040B2 true JP6648040B2 (ja) 2020-02-14

Family

ID=54699806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016569606A Active JP6648040B2 (ja) 2014-05-28 2015-05-28 がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用

Country Status (4)

Country Link
US (1) US10238630B2 (enExample)
EP (1) EP3148336B1 (enExample)
JP (1) JP6648040B2 (enExample)
WO (1) WO2015184145A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45324E1 (en) 2004-06-03 2015-01-06 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin B
US20120058178A1 (en) 2009-03-30 2012-03-08 Eisai R&D Management Co., Ltd. Liposome Composition
RU2672585C2 (ru) 2013-06-26 2018-11-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
ITUB20159206A1 (it) * 2015-12-22 2017-06-22 Olon Spa Forme cristalline e amorfe di olaparib
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
KR20190015361A (ko) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
CN109640992A (zh) * 2016-06-29 2019-04-16 泰萨罗公司 治疗卵巢癌的方法
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
IL268305B2 (en) 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
CA3052330A1 (en) * 2017-02-06 2018-08-09 City Of Hope Treatment of cancer
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
CA3063201A1 (en) 2017-05-09 2018-11-15 Tesaro, Inc. Combination therapies for treating cancer
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN107098862A (zh) * 2017-06-05 2017-08-29 山东裕欣药业有限公司 一种奥拉帕尼二水合物及其制备方法
JP7269227B2 (ja) * 2017-09-26 2023-05-08 テサロ， インコーポレイテッド ニラパリブ処方物
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. COMBINATION THERAPIES FOR TREATMENT OF CANCER
EA202090655A1 (ru) 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
KR20200118117A (ko) * 2018-02-05 2020-10-14 테사로, 인코포레이티드 소아용 니라파립 제제 및 소아용 치료 방법
CN112292463A (zh) * 2018-05-15 2021-01-29 肿瘤学风险公司 用于预测癌症患者药物反应性的方法
CA3125197A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
WO2022217060A1 (en) * 2021-04-09 2022-10-13 Cardiff Oncology, Inc. Cancer treatment using parp inhibitors and plk1 inhibitors
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
WO2024054898A1 (en) * 2022-09-08 2024-03-14 Cardiff Oncology, Inc. Onvansertib and parp inhibitor combination
JP2025530296A (ja) 2022-09-11 2025-09-11 カーディフ・オンコロジー・インコーポレイテッド 転移性癌を治療するためのｐｌｋ１阻害剤と抗血管新生剤の併用
WO2024137738A1 (en) * 2022-12-22 2024-06-27 The Board Of Regents Of The University Of Oklahoma Combinations of poly (adp-ribose) polymerase (parp) inhibitors and heteroarotinoids and methods of use as cancer treatments
AU2024234090A1 (en) * 2023-03-10 2025-10-02 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
ES2504690T3 (es) * 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
CA2828959A1 (en) * 2011-03-18 2012-09-27 Eisai R&D Management Co., Ltd. Methods and compositions for predicting response to eribulin
KR101923250B1 (ko) * 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료

Also Published As

Publication number Publication date
WO2015184145A8 (en) 2016-02-04
EP3148336A1 (en) 2017-04-05
US10238630B2 (en) 2019-03-26
EP3148336A4 (en) 2017-12-13
WO2015184145A1 (en) 2015-12-03
EP3148336B1 (en) 2019-10-02
JP2017516784A (ja) 2017-06-22
US20170100368A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
JP6648040B2 (ja) がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
CN106860870B (zh) 抗肿瘤生物碱的联合治疗
AU2008254273B2 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
AU2016309002A1 (en) Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment
EP3148526B1 (en) Use of eribulin in the treatment of cancer
HUP0302130A2 (hu) Kombinációs gyógyszerkészítmény és eljárás az előállításukra
MX2013013014A (es) Metodo para el tratamiento de tumores solidos avanzados.
JP2019511529A (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
WO2016081773A2 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
CN112891353B (zh) 药物组合及其用途
TW202521120A (zh) 藥物組合物及其應用
CN120529906A (zh) 用于治疗癌症的组合疗法
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
CN116672345A (zh) Parp抑制剂和细胞毒性剂的联合产品及其用途
EP4640218A1 (en) Use of sultam compound in treating biliary tract cancer
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
CN120476129A (zh) 配位化合物、组合物及其用于治疗癌症的用途
HK40026959A (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
NZ786609A (en) Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
HK1227400A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
HK1227400B (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200115

R150 Certificate of patent or registration of utility model

Ref document number: 6648040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250